Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Umeclidinium Bromide Powder for Inhalation

Approval Number

H20190070

CompanyGlaxo Group Ltd.

Registration Date

December 26, 2019

Drug Information

Generic Name

乌美溴铵吸入粉雾剂

Dosage Form

吸入粉雾剂

Strength

乌美溴铵(以乌美铵计)62.5μg

Drug Type

化学药品

Registration Date

December 26, 2019

Expiry Date

December 25, 2024

Company Information

Applicant Company

Company NameGlaxo Group Ltd.

Company Address

980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom

Manufacturing Company

Company NameGlaxo Operations UK Ltd.

Company Address

Priory Street,Ware,Hertfordshire SG12 0DJ,United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy